Skip to main content
TipRanks
Go Ultimate75% OFF

Eli Lilly & Co (LLY) Operating Expense Breakdown

23,974 Followers

Operating Expense Breakdown

Eli Lilly & Co reported operating expenses of $11.86B in Q3 2026, up 10.5% from Q2 2026 and up 64.1% year over year. This is the highest value since 2016.

Details spending on R&D, selling/general/admin and manufacturing to show how Lilly allocates cash between developing new drugs and running its commercial operations. Highlights whether the company is investing for long‑term growth, where cost pressure may hit margins, and how efficiently management turns spending into revenue.

$0.00$2.50B$5.00B$7.50B$10.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Lilly is deliberately ratcheting up recurring R&D and marketing/S&A to fund massive new product launches, international rollouts and manufacturing scale, while large, episodic acquired IPR&D and impairment items from aggressive M&A create pronounced lumpiness. Management absorbed hefty IPR&D charges in Q2 yet still raised guidance thanks to strong top‑line leverage, so current spend is driving durable growth but also earnings volatility; watch future IPR&D/impairment timing and MS&A cadence to judge whether margin gains persist as launch noise, pricing pressure and H2 seasonality normalize.

LLY Operating Expense Breakdown

PeriodResearch and DevelopmentMarketing, Selling, and AdministrativeAcquired In-Process Research and DevelopmentImpairment, Restructuring, and OtherTotal
Q3 2026Sep 30, 2026$4.25B$3.13B$4.18B$303.00M$11.86B
Q2 2026Jun 30, 2026$3.82B$3.43B$2.78B$703.00M$10.73B
Q1 2026Mar 31, 2026$3.51B$2.93B$584.00M$279.00M$7.31B
Q4 2025Dec 31, 2025$3.80B$3.13B$528.80M$84.10M$7.55B
Q3 2025Sep 30, 2025$3.47B$2.74B$655.70M$364.90M$7.23B
Q2 2025Jun 30, 2025$3.34B$2.75B$153.80M$0.00$6.24B
Q1 2025Mar 31, 2025$2.73B$2.47B$1.57B$35.00M$6.81B
Q4 2024Dec 31, 2024$3.02B$2.42B$189.20M$344.00M$5.98B
Q3 2024Sep 30, 2024$2.73B$2.10B$2.83B$81.60M$7.74B
Q2 2024Jun 30, 2024$2.71B$2.12B$154.30M$435.00M$5.42B
Q1 2024Mar 31, 2024$2.52B$1.95B$110.50M$0.00$4.59B
Q4 2023Dec 31, 2023$2.56B$1.92B$622.60M$6.77M$5.12B
Q3 2023Sep 30, 2023$2.41B$1.80B$2.98B$0.00$7.19B
Q2 2023Jun 30, 2023$2.36B$1.93B$97.10M$0.00$4.38B
Q1 2023Mar 31, 2023$1.99B$1.75B$105.00M$0.00$3.84B
Q4 2022Dec 31, 2022$2.00B$1.64B$240.10M$38.10M$3.92B
Q3 2022Sep 30, 2022$1.80B$1.61B$62.40M$206.50M$3.69B
Q2 2022Jun 30, 2022$1.78B$1.63B$440.40M$0.00$3.85B
Q1 2022Mar 31, 2022$1.61B$1.56B$165.60M$0.00$3.33B
Q4 2021Dec 31, 2021$1.96B$1.59B$437.70M$104.50M$4.09B
Q3 2021Sep 30, 2021$1.71B$1.58B$177.60M$0.00$3.46B
Q2 2021Jun 30, 2021$1.67B$1.69B$42.80M$0.00$3.40B
Q1 2021Mar 31, 2021$1.68B$1.58B$312.00M$211.60M$3.78B
Q4 2020Dec 31, 2020$1.84B$1.55B$366.30M-$30.10M$3.73B
Q3 2020Sep 30, 2020$1.47B$1.57B$0.00$101.40M$3.14B
Q2 2020Jun 30, 2020$1.39B$1.45B$241.80M$0.00$3.08B
Q1 2020Mar 31, 2020$1.39B$1.55B$52.30M$59.90M$3.05B
Q4 2019Dec 31, 2019$1.58B$1.70B$0.00$151.70M$3.43B
Q3 2019Sep 30, 2019$1.38B$1.41B$77.70M$0.00$2.87B
Q2 2019Jun 30, 2019$1.40B$1.59B$25.00M$0.00$3.01B
Q1 2019Mar 31, 2019$1.23B$1.52B$136.90M$423.90M$3.31B
Q4 2018Dec 31, 2018$1.45B$1.86B$329.40M$246.00M$3.89B
Q3 2018Sep 30, 2018$1.34B$1.62B$30.00M$83.30M$3.07B
Q2 2018Jun 30, 2018$1.33B$1.65B$1.62B$74.40M$4.69B
Q1 2018Mar 31, 2018$1.18B$1.50B$0.00$78.30M$2.76B
Q4 2017Dec 31, 2017$1.47B$1.78B$50.00M$1.00B$4.31B
Q3 2017Sep 30, 2017$1.32B$1.56B$205.00M$406.50M$3.49B
Q2 2017Jun 30, 2017$1.25B$1.71B$0.00$50.00M$3.01B
Q1 2017Mar 31, 2017$1.24B$1.54B$857.60M$213.90M$3.85B
Q4 2016Dec 31, 2016$1.45B$1.79B$30.00M$147.60M$3.42B
Q3 2016Sep 30, 2016$1.24B$1.57B$0.00$45.50M$2.85B
Q2 2016Jun 30, 2016$1.34B$1.62B$0.00$58.00M$3.02B
Q1 2016Mar 31, 2016$1.22B$1.47B$0.00$131.40M$2.83B

Related KPIs